Antiarrythmic Drugs - Long-term Follow-up in the Modern Era
Information source: University of Dundee
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cardiac Dysrhythmia
Phase: N/A
Status: Active, not recruiting
Sponsored by: University of Dundee
Summary
Antiarrhythmic drugs are associated with significant side effect profiles. Amiodarone has
primarily class III action and whilst it has unrivalled efficacy in management of certain
arrhythmias, it has a formidable side effect profile. Complications of continued therapy
include, thyroiditis, hepatitis, cholestasis, increased skin sensitivity and pulmonary
fibrosis. Current prescribing guidelines recommend frequent blood tests to monitor kidney,
liver and thyroid function, in addition to frequent pulmonary function tests. Sotalol is a
betablocker which possesses class III action in high doses and may predispose to QT
prolongation Other class I agents such as flecainide and propafenone can be associated with
sudden cardiac death in certain populations, and may predispose to other arrhythmias.
This study will examine the incidence of discontinuation of AAD therapy and adverse events.
Clinical Details
Official title: Retrospective Record Linkage Study to Investigate the Incidence of Complications and Follow-up Associated With Anti-arrythmic Drug Therapy
Study design: Observational Model: Ecologic or Community, Time Perspective: Retrospective
Primary outcome: Adverse Event
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- At least one prescription for antiarrythmic drug
Locations and Contacts
Univeristy of Dundee, Dundee DD1 9SY, United Kingdom
Additional Information
Starting date: March 2010
Last updated: March 4, 2010
|